The financing will provide capital to accelerate product development and fund a series of multicenter clinical studies to establish safety and efficacy of the company’s patented neuromodulation system.
More Articles on Devices:
Mazor Robotics 2013 Net Loss Shoots to $20M
Advancement in Lateral Spine Technology: Q&A with Vertebral Technologies, Inc. CEO Dr. Jeffrey Felt
EDGE Orthopaedics Receives FDA 510(k) Clearance for BITE Compression Screws
